Biosimilar medicines used for cancer therapy in Europe: a review

Santos, Sofia B.; Lobo, José M. Sousa; Silva, Ana Catarina

http://hdl.handle.net/10284/9807

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Silva AC and Santos S_Drug Discovery Today.pdf		397.09 KB	Adobe PDF	Download

Send Feedback

Authors

Santos, Sofia B.

Lobo, José M. Sousa

Silva, Ana Catarina

Abstract(s)

This article provides an updated review of the biosimilar medicines approved for cancer therapy in the European Union (EU). First we discuss the most relevant aspects for the development and approval of biosimilar medicines. We then present the oncological biosimilar drugs currently used, which include epoetins (alpha and zeta), filgrastim, and monoclonal antibodies (rituximab, trastuzumab and bevacizumab). Among the clinical applications of biosimilar medicines, cancer therapy remains the main target area and more approved biosimilars are expected over the next few years, providing cost-effective drugs to more patients. Furthermore, comprehensive pharmacovigilance studies are going on, monitoring the marketed biosimilars, and providing more feasible information to clinicians regarding the safety and efficacy of these medications.